NMS 1286937

Drug Profile

NMS 1286937

Alternative Names: NMS-1286937; NMS-P937

Latest Information Update: 12 May 2016

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 12 May 2016 Chemical structure information added
  • 09 May 2016 Phase-I development is ongoing in Canada
  • 02 Dec 2009 Phase-I clinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top